A randomised trial comparing gemcitabine vs TS-1 in patients with resected pancreatic cancer.

A randomised trial comparing gemcitabine vs TS-1 in patients with resected pancreatic cancer. - A randomised trial comparing gemcitabine vs TS-1

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009118

Enrollment

Registered

2012-10-15

Start date

2008-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resected pancreas cancer

Interventions

GEM TS-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients never had malignacy before pancreas cancer.

Exclusion criteria

Exclusion criteria: age allegy Patietns aggremant

Design outcomes

Primary

Measure	Time frame
time to recurrence	—

Secondary

Measure	Time frame
over all survival safty	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactMitsugi Shimoda

Dokkyo Medical University Second Department of Surgery

shimodamitsugi@hotmail.com0283-87-2158

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026